Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has been assigned an average rating of “Buy” from the six brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $9.00.
A number of research firms have recently weighed in on PIRS. HC Wainwright set a $9.00 target price on Pieris Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, December 20th. ValuEngine downgraded Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st.
In other news, major shareholder Orbimed Advisors Llc sold 147,635 shares of Pieris Pharmaceuticals stock in a transaction on Monday, December 18th. The stock was sold at an average price of $5.70, for a total transaction of $841,519.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.05% of the stock is currently owned by company insiders.
Shares of Pieris Pharmaceuticals (NASDAQ PIRS) traded up $0.11 during trading on Tuesday, reaching $6.37. The company’s stock had a trading volume of 348,900 shares, compared to its average volume of 613,037. Pieris Pharmaceuticals has a fifty-two week low of $1.38 and a fifty-two week high of $6.65. The firm has a market cap of $328.79, a P/E ratio of -8.73 and a beta of -76.07.
Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative return on equity of 221.93% and a negative net margin of 321.83%. The company had revenue of $3.93 million during the quarter, compared to the consensus estimate of $1.52 million. The business’s quarterly revenue was up 400.3% compared to the same quarter last year. analysts expect that Pieris Pharmaceuticals will post -0.72 earnings per share for the current fiscal year.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.